Elite Pharmaceuticals director buys 30,000 shares at $0.287

ELITE PHARMACEUTICALS INC (ELTP) director Barry H Dash reported purchasing 30,000 shares of common stock on August 19, 2026, in a purchase described as an open market or private transaction at $0.287 per share.

Rhea-AI Filing Summary

ELITE PHARMACEUTICALS INC (ELTP) director Barry H Dash reported purchasing 30,000 shares of common stock on August 19, 2026, in a purchase described as an open market or private transaction at $0.287 per share.

After this buy, he directly owns 3,265,555 shares of ELTP common stock, and no Rule 10b5-1 plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 30,000 shares

Net Buy 1 txn

Insider Dash Barry H

Role Director

Bought 30,000 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	30,000	$0.287	$9K

Holdings After Transaction: Common Stock — 3,265,555 shares (Direct)

Key Figures

Shares purchased: 30,000 shares Price per share: $0.287 per share Shares owned after transaction: 3,265,555 shares

3 metrics

Shares purchased 30,000 shares Common stock bought on August 19, 2026 in an open market or private transaction

Price per share $0.287 per share Purchase price for the 30,000 ELTP common shares on August 19, 2026

Shares owned after transaction 3,265,555 shares Total direct ELTP common stock holdings of Barry H Dash following the purchase

Key Terms

open market or private transaction, Rule 10b5-1 plan, direct ownership

3 terms

open market or private transaction financial

"Purchase in open market or private transaction description"

Rule 10b5-1 plan regulatory

"No Rule 10b5-1 plan is reported for this transaction"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

direct ownership financial

"He directly owns 3,265,555 shares of ELTP common stock"

FAQ

What insider transaction was reported for ELTP on August 19, 2026?

A director of ELITE PHARMACEUTICALS INC, Barry H Dash, reported buying 30,000 shares of ELTP common stock on August 19, 2026 in a purchase described as an open market or private transaction at $0.287 per share.

How many ELTP shares does Barry H Dash own after this Form 4 transaction?

Following the reported purchase, Barry H Dash directly owns 3,265,555 shares of ELITE PHARMACEUTICALS INC common stock. This figure reflects his total direct holdings after acquiring 30,000 additional shares.

Was the ELTP insider trade made under a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not affirmed, so no Rule 10b5-1 trading plan is reported in connection with this 30,000-share purchase of ELTP common stock.

What price did the ELTP director pay per share in this transaction?

The director’s reported purchase of ELITE PHARMACEUTICALS INC common stock was at $0.287 per share. The filing describes this as a purchase in an open market or private transaction.

Is the reported ELTP insider transaction a buy or a sell?

The reported insider transaction for ELTP is a buy. Barry H Dash purchased 30,000 shares of ELITE PHARMACEUTICALS INC common stock and increased his direct holdings to 3,265,555 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 01:30 PM Accepted by SEC EDGAR 09/10/2026 - 01:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dash Barry H

(Last) (First) (Middle)

C/O ELITE PHARMACEUTICALS, INC.

165 LUDLOW AVE

(Street)

NORTHVALE NEW JERSEY 07647

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELITE PHARMACEUTICALS INC /NV/ [ ELTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		P		30,000	A	$0.287	3,265,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Barry Dash	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)